Page 343 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 16 Supportive Care for the Cancer Patient 321

77. Williams MD, Kirkpatrick AE, Griffith E, et al.: Feasibility and 97. Timoshenko AV, Chakraborty C, Wagner GF, et al.: COX-
repeatability of thermal quantitative sensory testing in normal 2-mediated stimulation of the lymphangiogenic factor VEGF-C in
dogs and dogs with hind limb osteoarthritis-associated pain, Vet J human breast cancer, Br J Cancer 94:1154–1163, 2006.
VetBooks.ir 78. Bergh MS, Budsberg SC: The coxib NSAIDs: potential clinical and 98. Xin X, Majumder M, Girish GV, et al.: Targeting COX-2 and EP4
199:63–67, 2014.
to control tumor growth, angiogenesis, lymphangiogenesis and
pharmacologic importance in veterinary medicine, J Vet Intern Med
19:633–643, 2005. metastasis to the lungs and lymph nodes in a breast cancer model,
Lab Investig 92:1115–1128, 2012.
79. Papich MG: An Update on nonsteroidal anti-inflammatory drugs 99. Smith HS: Potential analgesic mechanisms of acetaminophen, Pain
(NSAIDs) in small animals, Vet Clin North Am Small Anim Pract Physician 12:269–280, 2009.
38:1243–1266, 2008. 100. Mburu DN: Evaluation of the anti‐inflammatory effects of a low
80. Innes JF, Clayton J, Lascelles BDX: Review of the safety and effi- dose of acetaminophen following surgery in dogs, J Vet Pharmacol
cacy of long-term NSAID use in the treatment of canine osteoar- Ther 14(109–111), 1991.
thritis, Vet Rec 166:226–230, 2010. 101. Klinger RY, Habib AS: Acetaminophen and ondansetron: the cen-
81. Kukanich B, Bidgood T, Knesl O: Clinical pharmacology of tral serotonergic connection, J Clin Anesth 40:101–102, 2017.
nonsteroidal anti-inflammatory drugs in dogs, Vet Anaesth Analg 102. Saliba SW, Marcotegui AR, Fortwängler E, et al.: AM404,
39:69–90, 2012. paracetamol metabolite, prevents prostaglandin synthesis in acti-
82. Belshaw Z, Asher L, Dean RS: The attitudes of owners and vet- vated microglia by inhibiting COX activity, J Neuroinflammation
erinary professionals in the United Kingdom to the risk of adverse 14:246, 2017.
events associated with using non-steroidal anti-inflammatory drugs 103. Pickering G, Loriot M, Libert F, Eschalier A, Beaune PDC: Anal-
(NSAIDs) to treat dogs with osteoarthritis, Prev Vet Med 131:121– gesic effect of acetaminophen in humans: first evidence of a central
126, 2016. serotonergic mechanism, Clin Pharmacol Ther 79:371–378, 2006.
83. Duncan B, Lascelles X, McFarland JM, et al.: Guidelines for safe 104. Ottani A, Leone S, Sandrini M, et al.: The analgesic activity of
and effective use of NSAIDs in dogs, Vet Ther 6:237–251, 2005. paracetamol is prevented by the blockade of cannabinoid CB1
84. Monteiro-Steagall BP, Steagall PVM, Lascelles BDX: systematic receptors, Eur J Pharmacol 531:280–281, 2006.
review of nonsteroidal anti-inflammatory drug-induced adverse 105. Mallet C, Barrière DA, Ermund A, et al.: TRPV1 in brain is
effects in dogs, J Vet Intern Med 27:1011–1019, 2013. involved in acetaminophen-induced antinociception, PLoS One
85. Robertson SA: Osteoarthritis in cats: what we now know about 5:1–11, 2010.
recognition and treatment, Vet Med 103:611–616, 2008. 106. Andersson DA, Gentry C, Alenmyr L, et al.: TRPA1 mediates spi-
86. Adrian D, Papich M, Baynes R, et al.: Chronic maladaptive pain nal antinociception induced by acetaminophen and the cannabi-
in cats: a review of current and future drug treatment options, Vet J noid Δ9-tetrahydrocannabiorcol, Nat Commun 2:551, 2011.
230:52–61, 2017. 107. Mburu DN, Mbugua SW, Skoglund LA, et al.: Effects of
87. Hunt JR, Dean RS, Davis GND, et al.: An analysis of the rela- paracetamol and acetylsalicylic acid on the post‐operative course
tive frequencies of reported adverse events associated with NSAID after experimental orthopaedic surgery in dogs, J Vet Pharmacol
administration in dogs and cats in the United Kingdom, Vet J Ther 11:163–171, 1988.
206:183–190, 2015. 108. Kukanich B, Papich MG: Pharmacokinetics of tramadol and the
88. Budsberg SC, Torres BT, Kleine SA, et al.: Lack of effectiveness of metabolite O-desmethyltramadol in dogs, J Vet Pharmacol Ther
tramadol hydrochloride for the treatment of pain and joint dys- 27:239–246, 2004.
function in dogs with chronic osteoarthritis, J Am Vet Med Assoc 109. Kukanich B, Lascelles BDX, Aman AM, et al.: The effects of
252:427–432, 2018. inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid
89. Nakao K, Murase A, Ohshiro H, et al.: CJ-023, 423, a novel, secretion on the oral bioavailability of methadone in dogs, J Vet
potent and selective prostaglandin EP4 receptor antagonist with Pharmacol Ther 28:461–466, 2005.
antihyperalgesic properties, Pharmacology 322:686–694, 2007. 110. Kukanich B, Lascelles BDX, Papich MG: Pharmacokinetics of
90. Okumura T, Murata Y, Taniguchi K, et al.: Effects of the selective morphine and plasma concentrations of morphine-6-glucuronide
EP4 antagonist, CJ-023,423 on chronic inflammation and bone following morphine administration to dogs, J Vet Pharmacol Ther
destruction in rat adjuvant-induced arthritis, J Pharm Pharmacol 28:371–376, 2005.
60:723–730, 2008. 111. Kukanich B: Pharmacokinetics of acetaminophen, codeine, and
91. Rausch-Derra LC, Rhodes L, Freshwater L, et al.: Pharmacokinetic the codeine metabolites morphine and codeine-6-glucuronide in
comparison of oral tablet and suspension formulations of grapip- healthy Greyhound dogs, Vet Pharmacol Ther 33:15–21, 2009.
rant, a novel therapeutic for the pain and inflammation of osteoar- 112. Egger CM, Glerum LE, Allen SW, et al.: Plasma fentanyl concen-
thritis in dogs, J Vet Pharmacol Ther 39:566–571, 2016. trations in awake cats and cats undergoing anesthesia and ovario-
92. Nagahisa A, Okumura T: Pharmacology of grapiprant, a novel EP4 hysterectomy using transdermal administration, Vet Anaesth Analg
antagonist: receptor binding, efficacy in a rodent postoperative pain 30:229–236, 2003.
model, and a dose estimation for controlling pain in dogs, J Vet 113. Egger CM, Glerum L, Haag KM, et al.: Efficacy and cost-
Pharmacol Ther 40:285–292, 2017. effectiveness of transdermal fentanyl patches for the relief of post-
93. Rausch-Derra LC, Rhodes L: Safety and toxicokinetic profiles operative pain in dogs after anterior cruciate ligament and pelvic
associated with daily oral administration of grapiprant, a selective limb repair, Vet Anaesth Analg 34:200–208, 2007.
antagonist of the prostaglandin E2EP4 receptor, to cats, Am J Vet 114. Lascelles BDX, Robertson SA, Taylor PM, et al.: Comparison of
Res 77:688–692, 2016. the pharmacokinetics and thermal antinociceptive pharmacody-
94. Rozic JG, Chakraborty C, Lala PK: Cyclooxygenase inhibitors retard namics of 20 μg kg−1 buprenorphine administered sublingually or
murine mammary tumor progression by reducing tumor cell migra- intravenously in cats, Vet Anaesth Analg 30:99–119, 2003.
tion, invasiveness and angiogenesis, Int J Cancer 93:497–506, 2001. 115. Dayer P, Desmeules J, Collart L: Pharmacologie du tramadol,
95. Timoshenko AV, Xu G, Chakrabarti S, et al.: Role of prostaglandin Drugs 53:18–24, 1997.
E2 receptors in migration of murine and human breast cancer cells, 116. Oliva P, Aurilio C, Massimo F, et al.: The antinociceptive effect
Exp Cell Res 289:265–274, 2003. of tramadol in the formalin test is mediated by the serotonergic
96. Timoshenko AV, Lala PK, Chakraborty C: PGE2-mediated upreg- component, Eur J Pharmacol 445:179–185, 2002.
ulation of iNOS in murine breast cancer cells through the activa- 117. Leppert W: Tramadol as an analgesic for mild to moderate cancer
tion of EP4 receptors, Int J Cancer 108:384–389, 2004. pain, Pharmacol Reports 61:978–992, 2009.